Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients

Purpose Ado-trastuzumab emtansine (T-DM1) treatment in HER2+ advanced breast cancer patients is generally well tolerated, but when adverse events occur dose adjustments may be required. This study evaluated the impact of early adverse events requiring T-DM1 dose interruptions or reductions on overal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2019-11, Vol.178 (2), p.473-477
Hauptverfasser:	Tang, Ethan, Rowland, Andrew, McKinnon, Ross A., Sorich, Michael J., Hopkins, Ashley M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Ado-Trastuzumab Emtansine - administration & dosage Ado-Trastuzumab Emtansine - adverse effects Analysis Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Biomarkers, Tumor Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Brief Report Cancer research Care and treatment Clinical trials Complications and side effects ErbB-2 protein Female Humans Immunotherapy Kaplan-Meier Estimate Medical colleges Medicine Medicine & Public Health Metastases Metastasis Monoclonal antibodies Oncology Patient outcomes Patients Prognosis Proportional Hazards Models Receptor, ErbB-2 - metabolism Survival Targeted cancer therapy Trastuzumab Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!